ENDECE

ENDECE updated their business hours.

https://endece.com/ndc-1308-a-novel-therapeutic-for-acute-respiratory-distress-syndrome-ards-including-covid-19-patients/

As SARS-Cov-2 / COVID-19 continues to dominate our lives, the world is looking for a way to get back to “Normal”. Unfortunately, “Normal”, is a long ways off and may have to be redefined in general. ENDECE is excited about the promise of NDC-1308 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and specifically as a much needed treatment of ARDS in COVID-19 patients.

NDC-1308 a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS) including COVID-19 patients NDC-1308 is a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS) including SARS-CoV-2 and COVID-19 patients

ENDECE is proud to be a part of Wisconsin BioForward and the Wisconsin biohealth industry which stepped up to the challenge of fighting the COVID-19 pandemic. Please join us on January 14th at noon CST to hear from ENDECE and eight other organizations about how all our industry pushed forward to keep WI healthy. James Hoyes, ENDECE Board member and strategic advisor, will discuss ENDECE’s discovery and development of NDC-1308 for treating acute respiratory distress (ARDS), preventing respiratory failure, improving health outcomes, and reducing mortality in COVID-19 patients. https://www.eventbrite.com/e/wisconsin-biohealth-industrys-response-to-the-covid-19-pandemic-tickets-133866549453”

Wisconsin Biohealth Industry’s Response to the COVID-19 Pandemic Rapid-fire updates from BioForward member companies.

NDC-1308 A Therapeutic for COVID-19 And Other Pulmonary Viruses https://endece.com/ndc-1308-a-therapeutic-for-covid-19-and-other-pulmonary-viruses/

NDC-1308 A Therapeutic for COVID-19 And Other Pulmonary Viruses - ENDECE NDC-1308 A Therapeutic for COVID-19 And Other Pulmonary Viruses by Endece | Nov 12, 2020 To win the battle with SARS-CoV-2 we need a therapeutic designed to regain control of immune response. Historically vaccines have played an important role in the prevention of many diseases. However, the overall...

ENDECE developed NDC-1308, a novel COVID-19 therapeutic designed to reduce inflammation in the lungs as well as the number of ACE2 receptors in the pulmonary system, reducing the viral load. By reducing pulmonary inflammation and viral load, as well as preventing cytokine storm due to viral infections like SARS-CoV-2 / COVID-19, NDC-1308 should reduce long term effects, keep people off ventilators, and even prevent death.

https://endece.com/

https://endece.com/ndc-1308-a-novel-therapeutic-for-covid-19/

NDC-1308 A NOVEL THERAPEUTIC FOR COVID-19 ENDECE developed NDC-1308, a novel therapeutic for COVID-19 designed to reduce inflammation in the lungs as well as the number of ACE2 receptors

As a vaccine for COVID-19 may not be available soon, or even at all... therapeutics like NDC-1308 (Antiviral and Immunomodulating) may be the best way to save lives and slow the progression of this pandemic. https://www.washingtonpost.com/opinions/what-if-the-coronavirus-vaccine-doesnt-arrive-soon/2020/08/05/4a34029e-d5ab-11ea-9c3b-dfc394c03988_story.html

Opinion | What if the coronavirus vaccine doesn’t arrive soon? Suppose there’s no vaccine in two or four years. What would we wish we had done today?

Within the US alone, there are over 200,000 hospitalizations annually from seasonal viral influenza. Patients requiring mechanical ventilation have a high mortality rate of 20% or over 40,000 people annually.

https://endece.com/ndc-1308-mc1-therapeutic-for-seasonal-viral-influenza/

NDC-1308 (MC1) Therapeutic for Seasonal Viral Influenza NDC-1308 (MC1) will be an important treatment for lung inflammation and respiratory distress in seasonal influenza patients

https://endece.com/differences-between-ndc-1308-and-dexamethasone/

Differences between NDC-1308 and Dexamethasone The differences between NDC-1308 and Dexamethasone in COVID-19 patients support NDC-1308 may have increased efficacy in all COVID-19 patients

ENDECE updated their information in their About section.

Macrophage Inflammation In The Lungs https://endece.com/macrophage-inflammation-in-the-lungs/

ENDECE updated their website address.

A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome. To learn more go to Developing NDC-1308. http://endece.com/about/demyelinating-diseases/

ENDECE - About Demyelinating Diseases, damage to the myelin sheath

NDC-1308 to Induce Remyelination ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the dual mechanism of action that allows NDC-1308 to induce remyelination...

The following link is to a short video, with ENDECE scientists, explaining how NDC-1308 works to induce remyelination in demyelinating diseases such as multiple sclerosis (MS), neuromyelitis optica (NMOSD), and cognition in Alzheimer’s disease (AD). They also discuss preparations for clinical studies as well as when NDC-1308 might be approved for patient use. https://youtu.be/mVGsn24ZT8Y

NDC-1308 to Induce Remyelination ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the dual mechanism of action that allows NDC-1308 to induce remyelination...

What do researchers consider when developing a remyelination therapy?http://endece.com/wp-content/uploads/2017/03/ENDECE_Newsletter_Mar2017.pdf

endece.com

The “official” MS Awareness Month may be over, but we know MS patients, their dedicated advocates, researchers and physicians continue the fight every day!

In ENDECE's March 2017 Newsletter we take the time to answer many of the questions we have been asked over the past year.http://endece.com/wp-content/uploads/2017/03/ENDECE_Newsletter_Mar2017.pdf

endece.com

Registering for Walk MS in your local area is a great way to make a contribution to Multiple Sclerosis awareness. Find out more from Walk MS

Join us in supporting Rare Disease Day 2017 – This year’s slogan is 'With research, possibilities are limitless.’ We couldn’t agree more.

ENDECE announces a new office opening in San Francisco’s financial district. CEO James Yarger, Ph.D says the office with “facilitate our efforts to establish strategic partnerships and secure additional funding for our development programs.” http://bit.ly/2lW7tAg

ENDECE Opens San Francisco Office | Business Wire ENDECE announced that it is opening an office in San Francisco, establishing a West Coast presence that reinforces its commitment to advancing its pip

ENDECE Receives Additional U.S. Patent Covering NDC-1308 for Inducing Remyelination http://endece.com/endece-receives-additional-u-s-patent-covering-ndc-1308-for-inducing-remyelination/

ENDECE Receives Additional U.S. Patent Covering NDC-1308 for Inducing Remyelination | Endece ENDECE Receives Additional U.S. Patent Covering NDC-1308 for Inducing Remyelination July 12, 2016 Patent Strengthens ENDECE’s Intellectual Property and Clinical Development Programs for Potential Therapies to Treat Patients with Multiple Sclerosis (MS) and Other Neurological Diseases MEQUON, Wis.–(B...